Aggressive lymphoma: news on ASH 2014

This article reviews the most important news at American Society of Hematology (ASH) 2014 for the clinician. A validated risk model for central nervous system (CNS) relapse after rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) defined a low, intermediate, and a high risk group. The latter with a CNS-relapse risk of 12 %. Interim positron emission tomography (PET) imaging and different treatment strategies for positive disease were highly prognostic for an unfavorable prognosis. However, the salvage strategies for these patients were not successful. The role of radiotherapy was clarified in a randomized trial of non-bulky stage I or II disease. It was not possible to demonstrate an event-free (EFS) and overall (OS) survival benefit for radiation after 4–6 R-CHOP cycles. Unfortunately ofatumomab was not superior to rituximab in combination with DHAP in relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

ConclusionsPrimary central nervous system lymphoma is rare, even more so in the cerebellum. However, the overall incidence of primary central nervous system lymphoma is rising in both immunocompromised and immunocompetent patients. The highly aggressive nature of primary central nervous system lymphoma necessitates timely diagnosis and intervention. In this report, we review the available literature for a better understanding of the pathophysiology and management of primary central nervous system lymphoma. To the best of our knowledge, this is the first reported case of a patient with primary central nervous system lymphom...
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research
We describe a 32-year-old woman with spontaneous regression of HL and review the literature. The patient presented with cervical lymphadenopathy and was diagnosed with stage IIA classical HL. The patient refused to receive any treatment for her disease. Positron emission tomography/computed tomography carried out 2 years later showed complete regression of the lymphadenopathy, without pathological uptake of fluorodeoxyglucose. At the last follow-up, 3.5 years after the initial presentation, the patient is with no evidence of disease. During workup for the HL, concomitant papillary thyroid carcinoma was diagnosed, for which...
Source: Acta Haematologica - Category: Hematology Source Type: research
We describe a 32-year-old woman with spontaneous regression of HL and review the literature. The patient presented with cervical lymphadenopathy and was diagnosed with stage IIA classical HL. The patient refused to receive any treatment for her disease. Positron emission tomography/computed tomography carried out 2 years later showed complete regression of the lymphadenopathy, without pathological uptake of fluorodeoxyglucose. At the last follow-up, 3.5 years after the initial presentation, the patient is with no evidence of disease. During workup for the HL, concomitant papillary thyroid carcinoma was diagnosed, for which...
Source: Acta Haematologica - Category: Hematology Authors: Tags: Acta Haematol Source Type: research
AbstractPurposeIn 2014, we published the qPET method to quantify fluorodeoxyglucose positron emission tomography (FDG ‐PET) responses. Analysis of the distribution of the quantified signals suggested that a clearly abnormal FDG‐PET response corresponds to a visual Deauville score (vDS) of 5 and high qPET values ≥ 2. Evaluation in long‐term outcome data is still pending. Therefore, we analyzed progression‐ free survival (PFS) by early FDG‐PET response in a subset of the GPOH‐HD2002 trial for pediatric Hodgkin lymphoma (PHL).Patients/MethodsPairwise FDG ‐PET scans for initial staging and early response asses...
Source: Pediatric Blood and Cancer - Category: Cancer & Oncology Authors: Tags: RESEARCH ARTICLE Source Type: research
CONCLUSION: In a substantial proportion of patients, particularly in men, pSS remains undiagnosed until after lymphoma diagnosis. The study highlights the importance of pSS investigation in patients with lymphoma, especially MALT lymphoma, in the salivary glands. PMID: 30422723 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Rheumatology - Category: Rheumatology Authors: Tags: Scand J Rheumatol Source Type: research
CONCLUSION: The indigenous product demonstrated kinetics similar in lines with that of approved commercially available radiopharmaceuticals, with advantage of less HAMA (Human Anti Mouse Antibody) response due to the pharmaceutical being a chimeric antibody rather than murine antibody and hence could be safely administered in clinical settings. In none of the organs there was dose limiting radiation exposure (≥ 20Gy) at the proposed therapeutic doses of this indigenous 131I labeled rituximab product. PMID: 30413603 [PubMed - as supplied by publisher]
Source: Journal of Nuclear Medicine Technology - Category: Nuclear Medicine Tags: J Nucl Med Technol Source Type: research
The ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) regimen has been the standard treatment for advanced Hodgkin ’s lymphoma (aHL) in adults.(1) In the last decade, attempts have been made to improve outcomes with dose-intense regimens like BEACOPP and incorporation of integrated positron emission tomography- computerized tomography scan (PET-CT) guided therapy.(2-5) More recently, brentuximab vedotin in com bination with AVD has been shown to be superior to ABVD.(5) Routine upfront use of BEACOPP is not practicable in many centers and brentuximab is not economically viable at this point.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Authors: Cui Q, Vari F, Cristino AS, Salomon C, Rice GE, Sabdia MB, Guanzon D, Palma C, Mathew M, Talaulikar D, Jain S, Han E, Hertzberg MS, Gould C, Crooks P, Thillaiyampalam G, Keane C, Gandhi MK Abstract MicroRNA (miRNA)s are dysregulated in Diffuse large B-cell lymphoma (DLBCL), where they reflect the malignant B-cells and the immune infiltrate within the tumor microenvironment. There remains a paucity of data in DLBCL regarding cell-free (c-f) miRNA as disease response biomarkers. Immunosuppressive monocyte/macrophages, which are enriched in DLBCL, are disease response markers in DLBCL, with miRNA key regulato...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
AbstractDespite receiving rituximab ‐combined chemotherapy, follicular lymphoma (FL) patients often suffer tumor recurrence, and understand the cause of relapse in FL would thus significantly ameliorate the tumor therapeutics. Here we demonstrate that the TRA‐1‐60‐expressing cells are a unique population in FLs, converge to th e conventional stem cell marker Oct3/4 and ALDH1‐positive population, and resist current B‐lymphoma agents. TRA‐1‐60 expression was observed only in scattered lymphoma cells in FL tissues as well as resting B‐lymphocytes inside germinal centers. Retrospective comparison between the ...
Source: Cancer Science - Category: Cancer & Oncology Authors: Tags: Original Article Source Type: research
In conclusion, a 61% rate of PET avidity in biopsy‐confirmed MALT lymphoma was found, and it was correlated with tumor size and Ki‐67 score. Only tumor stage and localization were independently correlated with PFS and OS.
Source: Hematological Oncology - Category: Hematology Authors: Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
More News: Cancer & Oncology | Hematology | Lymphoma | PET Scan | Prednisone | Rituxan